3,5-T2 (3,5-Diiodo-L-Thyronine): The Complete 2026 Research Guide

3,5-T2 - formally 3,5-diiodo-L-thyronine - is the thyroid metabolite that researchers have spent the last three decades gradually pulling out of the shadows. Unlike T3 and T4, which act primarily by binding nuclear thyroid hormone receptors and driving gene transcription, 3,5-T2 operates through a fundamentally different channel: it binds directly to mitochondrial cytochrome c oxidase and elevates the rate of aerobic respiration in a matter of minutes, not hours. That distinction - non-genomic, rapid, mitochondria-first - is what separates T2 from everything else in the thyroid hormone family and explains why bioenergetic researchers have increasingly placed it at the center of metabolic rate discussions. Despite being a direct product of T3 catabolism and present in human serum at measurable concentrations, 3,5-T2 receives a fraction of the research attention that T3 and T4 do - a gap that the literature from the past decade has been slowly closing.

Research framing. This article reviews 3,5-T2 from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our /faq#legality page for full terms.

Research Grade · Discreet Worldwide Shipping

Wilson's T3+T2 Combo

Buy Now →

What Is 3,5-T2?

3,5-diiodo-L-thyronine is a naturally occurring metabolite of thyroid hormone metabolism. Its core structure is the thyronine scaffold - the same diphenyl ether backbone shared by T4, T3, and all other thyroid hormone forms - with two iodine atoms attached at positions 3 and 5 on the inner phenyl ring. T4 carries four iodine atoms (positions 3, 5, 3', 5'); T3 carries three (positions 3, 5, 3'). T2 carries two - and the specific positioning of those two iodines determines whether the molecule is biologically active.

There are two diiodo isomers of thyronine in the research literature. The first - and the one this guide covers - is 3,5-T2, with both iodines on the inner ring at positions 3 and 5. The second is 3,3'-T2, with one iodine on the inner ring (position 3) and one on the outer ring (position 3'). The naming convention reflects iodine position relative to the ether linkage: the unprimed numbers (3, 5) refer to the inner ring; the primed numbers (3', 5') refer to the outer ring.

Why does isomer identity matter? Because it is decisive for bioactivity. 3,5-T2 - both iodines inner-ring - is the metabolically active isomer with measurable effects on mitochondrial respiration, lipid oxidation, and metabolic rate. 3,3'-T2 - the mixed-ring isomer - has been evaluated in the same experimental models and found to have negligible metabolic activity. When researchers, fitness-supplement formulators, and clinical investigators refer to "T2" as a metabolically active compound, they are referring specifically to 3,5-T2. The isomers are not interchangeable, and a supplement label that says only "T2" without specifying 3,5-diiodothyronine leaves the critical question of isomer identity unresolved.

3,5-T2 is produced in vivo primarily by the deiodination of T3. The type 1 deiodinase (DIO1) removes the 3'-iodine from T3, yielding 3,5-T2 as a direct downstream product - a conversion step that, when impaired, produces the T3-to-T2 conversion bottleneck increasingly implicated in the plateau pattern observed in T3-protocol research subjects. Serum concentrations in healthy human subjects have been measured in the picomolar range - far lower than T3, which is itself present at lower concentrations than T4. The low circulating concentration historically led to 3,5-T2 being dismissed as a spent metabolite without independent biological importance. The cytochrome c oxidase binding data published from 1994 onward challenged that assumption directly.

How 3,5-T2 Differs from T3 and T4

The three main thyroid hormones in clinical and research use - T4, T3, and 3,5-T2 - differ not only in iodine count but in mechanism of action, pharmacokinetic profile, and impact on the hypothalamic-pituitary-thyroid (HPT) axis. The table below summarizes the four dimensions that matter most for researchers comparing these molecules.

Reading those four rows as a set reveals why 3,5-T2 occupies a distinct niche rather than simply being a weaker version of T3.

The receptor affinity row establishes that T2 is not a strong driver of the classical thyroid hormone signaling cascade. T3 has tight, high-affinity binding to both TRalpha and TRbeta nuclear receptors. T2 binds those same receptors at roughly 10-60x lower affinity depending on the receptor isoform and the experimental system - which means at physiological concentrations it contributes minimally to gene-level thyroid signaling. That is not a limitation for its mechanism; it is the mechanism. T2 is not trying to activate nuclear receptors.

The mechanism row is the key differentiator. T3 and T4 (via conversion) work through a 6-48 hour cycle of receptor binding, gene transcription, mRNA production, and protein synthesis before metabolic effects are measurable at the whole-organism level. 3,5-T2 bypasses that entire cycle by binding directly to cytochrome c oxidase in the mitochondrial inner membrane - an interaction that elevates aerobic respiration acutely, within minutes. This is the defining property of T2 and the basis for most of its research interest.

The half-life row matters for research protocol design. T4's 7-day half-life gives it the most stable serum presence but the slowest dose-response relationship. T3's ~24-hour half-life means serum levels move meaningfully within a day of a dose change. T2's shorter half-life (measured in hours) means its mitochondrial effects are more transient - a characteristic that has implications for both its safety profile and for dosing strategy.

The TSH suppression row explains why T2 has attracted interest as an adjunct to T3 protocols. Because T2 is a much weaker driver of TSH suppression than T3, research subjects can receive T2 supplementation without triggering the aggressive HPT-axis downregulation that limits T3 escalation. For more detailed side-by-side analysis of all three hormones across additional parameters, see our T2 vs T3 vs T4 thyroid hormone comparison.

Mitochondrial Mechanism: Cytochrome c Oxidase

The mechanism that distinguishes 3,5-T2 from every other thyroid hormone form is its direct, non-genomic binding to cytochrome c oxidase - the terminal enzyme of the mitochondrial electron transport chain, also known as Complex IV. The landmark paper establishing this was published by Goglia, Lanni, and colleagues in FEBS Letters in 1994, demonstrating that 3,5-T2 directly stimulates cytochrome c oxidase activity in rat liver mitochondria independently of nuclear receptor involvement and independently of protein synthesis.

Specifically, 3,5-T2 binds to subunit Va of the cytochrome c oxidase complex. Subunit Va is one of the nuclear-encoded subunits of the 13-subunit Complex IV assembly, and it sits at a regulatory interface that modulates the enzyme's maximal activity. When 3,5-T2 occupies this binding site, Complex IV activity increases - meaning more electrons are transferred to molecular oxygen, proton pumping across the inner mitochondrial membrane accelerates, and the rate of aerobic ATP production and oxygen consumption rises.

The consequence at the whole-cell and whole-organism level is a rapid elevation in resting metabolic rate and basal oxygen consumption. This is measurable by indirect calorimetry in animal models within minutes of T2 administration - a time frame that is simply not compatible with the genomic transcription route. T3 requires hours to days to produce measurable whole-body metabolic rate changes because it must first bind nuclear receptors, drive transcription of target genes (including mitochondrial biogenesis factors and metabolic enzymes), and wait for the resulting proteins to accumulate to physiologically relevant concentrations. T2 produces its effect in real time by directly upregulating the enzyme that is already present in the mitochondrial membrane.

This speed contrast has practical implications for research protocol design. Researchers interested in acute bioenergetic changes - rapid metabolic rate shifts, oxygen consumption experiments, thermogenesis measurements - find T2 a more direct tool than T3 for that purpose. Researchers interested in sustained shifts in thyroid hormone gene targets - receptor downregulation, mitochondrial biogenesis over weeks, long-term metabolic reprogramming - are studying a different layer of biology, one where T3 is the dominant actor. The most comprehensive protocols in the current literature use both molecules for this reason, exploiting T2's acute mitochondrial action alongside T3's genomic effects.

Lipid Metabolism and Fatty Acid Oxidation

Beyond its effects on Complex IV activity, 3,5-T2 has been studied extensively for its impact on hepatic lipid metabolism. Rodent-model research published from the early 2000s onward has consistently shown that 3,5-T2 administration accelerates fatty acid oxidation in the liver, reduces stored hepatic triglycerides, and lowers serum triglyceride and free fatty acid concentrations.

The mechanism connecting cytochrome c oxidase activation to fatty acid oxidation is straightforward: a higher electron transport chain activity creates greater demand for reducing equivalents (NADH and FADH2), which in turn creates greater demand for the beta-oxidation of fatty acids that generates those reducing equivalents. The mitochondria, in effect, upregulate their fuel-burning rate to match the elevated capacity of Complex IV to process electrons. Hepatic fatty acid oxidation accelerates as a downstream consequence of the same cytochrome c oxidase stimulation that drives the acute metabolic rate elevation.

The critical distinction from high-dose T3 therapy in the same rodent models is muscle tissue sparing. High doses of T3 - particularly at the suprathysiological doses sometimes used in research contexts - drive a catabolic state that includes accelerated protein turnover in skeletal muscle, resulting in muscle mass loss. This is one of the significant practical limitations of high-dose T3 as a research or clinical tool. In rodent studies directly comparing matched metabolic effects, 3,5-T2 achieves comparable lipid-lowering and triglyceride-reduction outcomes without the same degree of muscle protein catabolism. The proposed reason is mechanistic: because T2 does not strongly activate nuclear thyroid hormone receptors, it does not drive the genomic cascades - including upregulation of muscle-protein ubiquitin ligases - that underlie T3-associated muscle wasting.

This combination of hepatic lipid reduction and relative muscle sparing is one of the reasons 3,5-T2 appears in both the chronic-illness bioenergetic literature and the sports-physiology literature, two communities that rarely overlap on thyroid research topics. The lipid-metabolism data remain largely rodent-model based - the human metabolic trial literature on T2 is limited - and researchers should treat the translational extrapolation with appropriate caution.

TSH Suppression: Why T2 Doesn't Crush the HPT Axis

One of the most clinically relevant properties of 3,5-T2 - and one of the primary reasons it has attracted attention as an adjunct to T3 protocols - is its comparatively modest impact on the hypothalamic-pituitary-thyroid (HPT) axis.

TSH (thyroid-stimulating hormone) suppression is the main limiting factor in high-dose or extended T3 protocols. When exogenous T3 drives TSH below the reference range, the pituitary is signaling that it perceives supraphysiological thyroid hormone exposure. Sustained TSH suppression is associated - in the long-term human endocrinology literature - with increased cardiovascular risk (atrial fibrillation) and decreased bone mineral density. For research subjects on T3 protocols, TSH serves as the primary safety feedback metric: how hard is the HPT axis being suppressed by the current dose?

In rodent models, 3,5-T2 has been shown to have approximately 10x lower potency than T3 for TSH suppression at equivalent doses. The mechanistic reason aligns with the receptor affinity data: because T2 binds TRbeta - the receptor isoform primarily responsible for HPT-axis feedback - at a much lower affinity than T3, it produces proportionally less pituitary signaling for TSH downregulation. The mitochondrial cytochrome c oxidase stimulation can proceed at doses that would be well below the T3-equivalent threshold for meaningful TSH suppression.

In consumer tracking and research-subject self-reporting, oral 3,5-T2 doses below approximately 300 mcg/day generally do not produce measurable TSH suppression as a primary endpoint. This is not a universally validated clinical finding - the human TSH-suppression dose-response for oral T2 has not been studied in rigorous controlled trials - but it is consistent with the animal model data and with the lower nuclear receptor affinity that is well established in the biochemistry literature.

For research applications involving T3 plus T2 co-administration, the practical implication is significant. Adding T2 to an existing T3 protocol - at the 1:1 ratio implemented in the Wilson's T3+T2 Combo - enhances the bioenergetic effect of the combined protocol without proportionally increasing the HPT-axis load. The mitochondrial action contributed by T2 supplements the genomic action of T3 without the additional TSH suppression that would result from simply increasing the T3 dose to achieve the same metabolic output. That mechanistic logic - complementary, non-overlapping mechanisms; non-additive HPT-axis impact - is the pharmacological case for the T3+T2 combination approach.

The Current T2 Supplement Landscape

The commercial market for 3,5-T2 has matured considerably since the early 2010s, when T2 was primarily a research-chemical curiosity. The current landscape divides roughly into two categories, which differ substantially in framing, dose, and quality standards.

The first category is thyroid-optimization and bioenergetic-research products, typically formulated at approximately 100 mcg of 3,5-T2 per capsule and positioned for researchers working on metabolic rate, mitochondrial function, and thyroid hormone adjunct protocols. Products in this category are generally more transparent about isomer identity (specifying 3,5-diiodothyronine rather than generic "T2") and more likely to include third-party purity verification or Certificates of Analysis. The Wilson's T3+T2 Combo sits in this category - a 1:1 T3/T2 formulation designed for the research community working with thyroid hormone combination protocols.

The second category is fitness-market fat-burner supplements, where T2 appears as one ingredient among many in proprietary blends. Doses in this category vary widely and are frequently undisclosed ("proprietary blend" labeling), isomer specificity is often absent from labels, and purity standards are harder to verify. The fitness fat-burner category was responsible for a surge in T2 consumer interest around 2010-2014, when several high-stimulant supplements incorporated it alongside synephrine, caffeine, and other thermogenics. Regulatory attention following adverse-event reports from several products in that category led to reformulations, but T2 has remained present in a subset of the fitness-supplement market.

The honest assessment is that purity and dose accuracy across the T2 consumer market vary widely. Researchers sourcing T2 for laboratory use should prioritize suppliers who specify 3,5-diiodothyronine (not generic "T2"), provide HPLC-verified assay data or CoA documentation, and disclose the excipient profile of the finished formulation. Undisclosed or unverified T2 preparations introduce uncertainty into any research protocol that depends on accurate dosing.

Why T2 Is Gaining Attention Now

The renewed research interest in 3,5-T2 over the past several years reflects convergence from multiple directions, but the most important driver is a specific pattern being documented in the chronic-illness thyroid research community: the T3-protocol plateau.

Researchers working with T3-supplementation protocols - including the Wilson's WT3 protocol and combination T4+T3 approaches - have observed a consistent phenomenon in a subset of research subjects: initial symptom improvement followed by plateau or partial regression, despite continuing T3 administration at doses that should theoretically be sufficient. Several investigators have proposed that this plateau reflects a downstream conversion problem - specifically, that the deiodinase enzymes responsible for metabolizing T3 are either overactive (converting too much T3 to rT3) or, in the context of the T3-to-T2 pathway, underperforming in ways that leave cells T2-depleted despite adequate T3 supply. This hypothesis is developed in detail in our T3-to-T2 conversion and deiodinase dysfunction guide, which examines the DIO1/DIO3 balance, genetic deiodinase variants, and the evidence base for T2 supplementation as a way to bypass the conversion step entirely.

The bioenergetic research community has arrived at similar interest from a different angle. Researchers studying mitochondrial function in chronic fatigue, post-viral syndromes, and related conditions have noted that Complex IV activity is specifically impaired in several of these states. A compound that directly stimulates Complex IV through a non-genomic mechanism - as 3,5-T2 does - offers a more targeted intervention than either T3 or general thyroid hormone supplementation for that specific pathway. The growing body of post-COVID research on mitochondrial dysfunction has accelerated this line of inquiry, pulling T2 into discussions it would not have appeared in five years ago.

A third driver is the increasing availability of research-grade 3,5-T2 at documented purity. For much of the 2010s, researchers who wanted to work with T2 were limited to either fitness-market preparations of uncertain isomer identity and purity, or academic-chemical suppliers whose minimum order quantities and pricing were prohibitive for small-scale protocol research. The emergence of research-catalog suppliers - including the Wilson's T3+T2 Combo and its companion enhanced T3+T2 protocol guide - has lowered the barrier to entry for researchers who want to work with a defined, verified T2 preparation alongside their T3 work. The deeper analysis of who the T2 responder is - and why some research subjects benefit substantially more than others - is covered in the T3-to-T2 conversion problem post.

Frequently Asked Questions

What is 3,5-T2?

3,5-T2 (3,5-diiodo-L-thyronine) is a naturally occurring thyroid hormone metabolite with two iodine atoms at positions 3 and 5 of the inner phenyl ring of the thyronine scaffold. It is produced in vivo primarily by the deiodination of T3 and is present in human serum at low picomolar concentrations. Unlike T3 and T4, which act primarily through nuclear thyroid hormone receptors to drive gene transcription, 3,5-T2 acts through a non-genomic mechanism - direct binding to cytochrome c oxidase (Complex IV) in the mitochondrial inner membrane - producing a rapid increase in aerobic respiration and resting metabolic rate.

How does 3,5-T2 differ from T3?

T3 is the primary active thyroid hormone and acts mainly by binding nuclear TRalpha and TRbeta receptors to drive gene transcription, a process that takes hours to days to produce measurable metabolic effects. 3,5-T2 has roughly 10-60x lower affinity for those same nuclear receptors, so it contributes minimally to genomic thyroid signaling. Instead, T2 binds directly to mitochondrial cytochrome c oxidase and elevates cellular respiration within minutes - a completely different mechanism operating on a completely different time scale. T3's half-life is approximately 24 hours; T2's is measured in hours, meaning its mitochondrial effects are more transient and dose-frequency dependent.

Does T2 suppress TSH like T3?

In rodent models, 3,5-T2 has approximately 10x lower TSH-suppression potency than T3 at equivalent doses. This reflects its lower affinity for TRbeta, the nuclear receptor isoform that mediates pituitary feedback. Consumer-tracking data suggest that oral T2 doses below approximately 300 mcg/day generally do not produce meaningful TSH suppression, though this has not been formally studied in controlled human trials. The significantly lower HPT-axis impact of T2 compared to T3 is one of its primary advantages in research contexts where TSH is being used as a safety monitoring endpoint.

Can T2 cause hyperthyroidism?

At the doses used in research contexts (typically 100-300 mcg/day), 3,5-T2 is not expected to produce classic hyperthyroid symptoms such as palpitations, tachycardia, tremor, or anxiety - symptoms that are primarily driven by nuclear receptor-mediated genomic thyroid signaling. Because T2's nuclear receptor affinity is 10-60x lower than T3, it does not trigger the same HPT-axis downregulation or cardiovascular adrenergic symptoms that high-dose T3 produces. However, at very high doses - well above research protocol ranges - non-specific effects cannot be ruled out, and researchers should treat any thyroid-active compound with appropriate caution and monitoring.

What's the difference between 3,5-T2 and 3,3'-T2?

The two diiodothyronine isomers differ only in the position of their two iodine atoms: 3,5-T2 has both iodines on the inner phenyl ring (positions 3 and 5), while 3,3'-T2 has one on the inner ring (position 3) and one on the outer ring (position 3'). This positional difference is decisive for bioactivity. 3,5-T2 is the metabolically active isomer - it binds cytochrome c oxidase, elevates mitochondrial respiration, and produces measurable metabolic rate and lipid-oxidation effects. 3,3'-T2 has been evaluated in the same experimental models and found to have negligible metabolic activity. When researchers or supplement formulators reference "T2" as a biologically active compound, they mean 3,5-T2 specifically.

Is 3,5-T2 the same as the "T2" in fitness fat-burners?

Not reliably. Fitness fat-burner supplements that list "T2" on the label vary widely in whether they specify the isomer (3,5-diiodothyronine vs generic diiodothyronine), the dose, and the purity of the active compound. Some products in this category do contain verified 3,5-T2 at meaningful doses; many do not provide enough label information to determine this. Research-grade 3,5-T2 - specified as 3,5-diiodo-L-thyronine with HPLC-verified assay documentation - is a different category of product from generic fitness-supplement "T2" blends, and the two should not be treated as equivalent for research-protocol purposes.

Why combine T2 with T3 instead of taking T2 alone?

T2 and T3 act through complementary, non-overlapping mechanisms: T3 drives genomic thyroid signaling (gene transcription, receptor-mediated metabolic reprogramming) while T2 drives non-genomic mitochondrial activation (direct Complex IV stimulation). Used together, they address both layers of cellular energy metabolism simultaneously - something neither can do as effectively alone. The specific rationale for combination use in the context of deiodinase dysfunction - where T3 supplementation alone fails to restore adequate T2 levels in subjects with impaired T3-to-T2 conversion - is covered in depth in our T3-to-T2 conversion problem guide. The Wilson's T3+T2 Combo and the corresponding enhanced T3+T2 protocol implement this 1:1 combination at the dose ratios most commonly reported in the research literature.

What dose of T2 is used in research?

Animal model studies have used doses ranging from microgram-per-kilogram quantities up to several hundred micrograms per day in rodents, with measurable effects on mitochondrial respiration, hepatic lipid oxidation, and metabolic rate consistently observed. In human-relevant consumer-tracking and research-protocol discussions, the most commonly reported range is 100-300 mcg/day of 3,5-T2, typically in 1-2 divided doses. The 100 mcg capsule is the most common research-catalog unit. At the lower end of this range (100-150 mcg/day), the mitochondrial stimulation effect is present with minimal anticipated HPT-axis impact; at the upper end (250-300 mcg/day), researchers monitor TSH as a safety endpoint even though T2's suppression potency is substantially lower than T3's.

Closing Note

3,5-T2 represents a genuinely distinct layer of thyroid biology - one that operates at the mitochondria rather than the nucleus, on a timescale of minutes rather than days, and with an HPT-axis footprint far smaller than T3 at equivalent metabolic effect. For researchers working on bioenergetic insufficiency, T3-protocol optimization, or the specific question of deiodinase pathway dysfunction, it is increasingly difficult to develop a complete model without accounting for T2's role. The Wilson's T3+T2 Combo is the research-grade reference standard implementing the 1:1 T3/T2 ratio at documented purity - the appropriate starting point for any laboratory research into combined thyroid hormone bioenergetics. For the full range of thyroid research compounds, see our catalog.